Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
21 01 2019
Historique:
received: 08 04 2017
accepted: 10 10 2017
pubmed: 28 10 2017
medline: 4 9 2020
entrez: 28 10 2017
Statut: ppublish

Résumé

Accumulation of reactive oxygen species (ROS) promotes vascular disease in obesity, but the underlying molecular mechanisms remain poorly understood. The adaptor p66Shc is emerging as a key molecule responsible for ROS generation and vascular damage. This study investigates whether epigenetic regulation of p66Shc contributes to obesity-related vascular disease. ROS-driven endothelial dysfunction was observed in visceral fat arteries (VFAs) isolated from obese subjects when compared with normal weight controls. Gene profiling of chromatin-modifying enzymes in VFA revealed a significant dysregulation of methyltransferase SUV39H1 (fold change, -6.9, P < 0.01), demethylase JMJD2C (fold change, 3.2, P < 0.01), and acetyltransferase SRC-1 (fold change, 5.8, P < 0.01) in obese vs. control VFA. These changes were associated with reduced di-(H3K9me2) and trimethylation (H3K9me3) as well as acetylation (H3K9ac) of histone 3 lysine 9 (H3K9) on p66Shc promoter. Reprogramming SUV39H1, JMJD2C, and SRC-1 in isolated endothelial cells as well as in aortas from obese mice (LepOb/Ob) suppressed p66Shc-derived ROS, restored nitric oxide levels, and rescued endothelial dysfunction. Consistently, in vivo editing of chromatin remodellers blunted obesity-related vascular p66Shc expression. We show that SUV39H1 is the upstream effector orchestrating JMJD2C/SRC-1 recruitment to p66Shc promoter. Indeed, SUV39H1 overexpression in obese mice erased H3K9-related changes on p66Shc promoter, while SUV39H1 genetic deletion in lean mice recapitulated obesity-induced H3K9 remodelling and p66Shc transcription. These results uncover a novel epigenetic mechanism underlying endothelial dysfunction in obesity. Targeting SUV39H1 may attenuate oxidative transcriptional programmes and thus prevent vascular disease in obese individuals.

Identifiants

pubmed: 29077881
pii: 4565556
doi: 10.1093/eurheartj/ehx615
doi:

Substances chimiques

Reactive Oxygen Species 0
Repressor Proteins 0
Shc1 protein, mouse 0
Src Homology 2 Domain-Containing, Transforming Protein 1 0
RNA 63231-63-0
Jmjd2c protein, mouse EC 1.14.11.-
Jumonji Domain-Containing Histone Demethylases EC 1.14.11.-
Suv39h1 protein, mouse EC 2.1.1.
Methyltransferases EC 2.1.1.-
Histone-Lysine N-Methyltransferase EC 2.1.1.43
Ncoa1 protein, mouse EC 2.3.1.48
Nuclear Receptor Coactivator 1 EC 2.3.1.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-391

Auteurs

Sarah Costantino (S)

Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solnavägen, 171 76 Stockholm, Sweden.
Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, Switzerland.

Francesco Paneni (F)

Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solnavägen, 171 76 Stockholm, Sweden.
Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, Switzerland.

Agostino Virdis (A)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Shafaat Hussain (S)

Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solnavägen, 171 76 Stockholm, Sweden.

Shafeeq Ahmed Mohammed (SA)

Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solnavägen, 171 76 Stockholm, Sweden.
Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, Switzerland.

Giuliana Capretti (G)

Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Via di Grottarossa, 1035, Rome, Italy.

Alexander Akhmedov (A)

Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, Switzerland.

Kevin Dalgaard (K)

Department of Epigenetics, Max Planck Institute of Immunology, Stuebeweg 51, Freiburg, Germany.

Sergio Chiandotto (S)

Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Via di Grottarossa, 1035, Rome, Italy.

J Andrew Pospisilik (JA)

Department of Epigenetics, Max Planck Institute of Immunology, Stuebeweg 51, Freiburg, Germany.

Thomas Jenuwein (T)

Department of Epigenetics, Max Planck Institute of Immunology, Stuebeweg 51, Freiburg, Germany.

Marco Giorgio (M)

Department of Experimental Oncology, Institute of Oncology, Via Adamello 16, Milano, Italy.

Massimo Volpe (M)

Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Via di Grottarossa, 1035, Rome, Italy.
Department of Angio-Cardio-Neurology, IRCCS Neuromed, Pozzilli, Italy.

Stefano Taddei (S)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Thomas F Lüscher (TF)

Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, Switzerland.

Francesco Cosentino (F)

Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solnavägen, 171 76 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH